Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)

Health and Quality of Life Outcomes

Ingela Wiklund⁷  Wen-Hung Chen¹  Michael Beck⁴  Mireia Raluy-Callado⁷  Marianne Rohrbach²  Gisela Kalkum⁴  Catharina Whybra⁴  Guillem Pintos-Morell³  Rossella Parini⁶  Donald E Stull⁵  Uma Ramaswami⁸ 

[1] United BioSource Corporation, Bethesda, MD, USA;University Children's Hospital, Zurich, Switzerland;Department of Pediatrics, “Germans Trias i Pujol” Hospital, Universitat Autònoma de Barcelona, Badalona, Spain;Department of Pediatrics, University Medical Center, University of Mainz, Mainz, Germany;RTI Health Solutions, Manchester, UK;San Gerardo Hospital, Università Milano Bicocca, Monza, Italy;United BioSource Corporation, London, UK;The Willink Biochemical Genetics Unit, Genetic Medicine, St Mary’s Hospital, Manchester, UK

关键词: Psychometrics validation;    Paediatric Health and Pain Questionnaire;    Children;    Enzyme replacement therapy;    Fabry disease;   

Others  :  825093
DOI  :  10.1186/1477-7525-10-116

 received in 2012-02-14, accepted in 2012-09-14,  发布年份 2012

【 摘 要 】

Introduction

Common symptoms for children with Anderson-Fabry Disease (FD) such as acroparaesthesia and gastrointestinal manifestations can only be objectively assessed in patients using a valid instrument. To date, no such instrument exists.

Methods

A preliminary 40-item measure of symptoms and experience with FD, the Fabry-specific Paediatric Health and Pain Questionnaire (FPHPQ) was developed, but lacked a formal assessment of its measurement properties. The FPHPQ was used in the Fabry Outcome Survey (FOS), a registry for all patients with a confirmed diagnosis of FD who are receiving agalsidase alfa, or are treatment naïve and who are managed by physicians participating in FOS. After an item analysis to explore how items performed and combined into domains, a battery of psychometric analyses was performed to assess the measurement properties of this new instrument.

Results

Eighty-seven children (ages 4-18 years) completed the questionnaire. Twenty-three items in three subscales of the questionnaire emerged: pain associated with heat or exertion, pain associated with cold, and abdominal pain and fatigue symptoms. Internal consistency reliability for all three subscales was good (Cronbach alpha ≥ 0.84). Reliability was equally high for all age groups (4-7, 8-12, and 13-18). Test-retest reliability was high for all three subscales (intraclass correlation coefficient ≥ 0.74). Construct validity was demonstrated by moderate correlation with brief pain inventory (BPI), KINDL, and EQ-5D. Known group validity showed all subscales were able to discriminate between Fabry disease severity groups as classified by above or below median of the FOS MSSI (Mainz Severity Score Index) grade. The heat or exertion subscale was responsive to change in symptoms between responders and non-responders as defined by change in EQ-5D index scores between the first and second visit.

Conclusions

Preliminary results indicate that the measurement properties of FPHPQ are valid and reliable for assessing patient-reported symptoms of FD. The questionnaire could be a useful tool for clinicians to understand the progression of disease and monitor treatment effects. FPHPQ will be further validated and refined as the FOS registry is continuously adding more patients.

【 授权许可】

   
2012 Ramaswami et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]James WD, Berger TG, et al.: Andrews' Diseases of the Skin. Saunders Elsevier: Clinical Dermatology; 2006:538.
• [2]Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, et al.: Pediatric fabry disease. Pediatrics 2005, 115:e344-355.
• [3]Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
• [4]Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcao A, et al.: Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004, 12:87-92.
• [5]Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP: The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999, 105:151-156.
• [6]Rider JA, Rider DL: Batten disease: past, present, and future. Am J Med Genet Suppl 1988, 5:21-26.
• [7]Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP: Fabry disease: a review of current management strategies. QJM 2010, 103:641-659.
• [8]Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M: Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006, 95:86-92.
• [9]Hernberg-Ståhl E, In Fabry Disease: Perspectives from 5 Years of FOS: Organization and technical aspects of FOS – the Fabry Outcome Survey. Oxford: Oxford PharmaGenesis: Edited by Mehta A, Beck M, Sunder-Plassmann G; 2006.
• [10]Whybra C, Bahner F, Baron K, In Fabry Disease: Perspectives from 5 Years of FOS: Measurement of disease severity and progression in Fabry disease. Oxford: Oxford PharmaGenesis: Edited by Mehta A, Beck M, Sunder-Plassmann G; 2006:315-322.
• [11]Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, et al.: The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004, 65:299-307.
• [12]Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994, 23:129-138.
• [13]Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS: Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004, 20:309-318.
• [14]Cleeland CS: Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 2002, 91:43-47.
• [15]Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M: Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007, 96:122-127.
• [16]Bullinger M, Brutt AL, Erhart M, Ravens-Sieberer U: Psychometric properties of the KINDL-R questionnaire: results of the BELLA study. Eur Child Adolesc Psychiatry 2008, 17(Suppl 1):125-132.
• [17]Ravens-Sieberer U, Bullinger M: Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res 1998, 7:399-407.
• [18]Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316:736-741.
• [19]Brooks R: EuroQol: the current state of play. Health Policy 1996, 37:53-72.
• [20]Hoffmann B, Garcia-de-Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005, 42:247-252.
• [21]Hoffmann B, Schwarz M, Mehta A, Keshav S: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007, 5:1447-1453.
• [22]StataCorp: Stata Statistical Software. StataCorp LP: Release 11. College Station, TX; 2009.
• [23]Muthén LK, Muthén B: Mplus User’s Guide. Muthén & Muthén, Los Angeles, CA; 1998-2004.
• [24]Leidy NK, Revicki DA, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2:113-127.
• [25]Nunnally JC, Bernstein IH: Psychometric Theory. 3rd edition. New York: McGraw-Hill; 1994.
• [26]Cohen J: A coefficient of agreement for nominal scales. Educ Psycho Meas 1960, 20:37-46.
• [27]Food and Drug Administration: Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register 2009, 74:65132-65133.
• [28]Hoffmann B, In Fabry Disease: Perspectives from 5 Years of FOS: Chapter 40: Effects of enzyme replacement therapy on pain and overall quality of life. Oxford: Oxford PharmaGenesis: Edited by Mehta A, Beck M, Sunder-Plassmann G; 2006.
• [29]Beck M, In Fabry Disease: Perspectives from 5 Years of FOS: Chapter 15: Demographics of FOS – the Fabry Outcome Survey. Oxford: Oxford PharmaGenesis: Edited by Mehta A, Beck M, Sunder-Plassmann G; 2006.